doctor The Food and Drug Administration (FDA) has approved the drug Vyleesi, which will help pre-menopausal women who have lost their sexual desire
The healed substance, bromelanotide, works by activating brain activations that affect sexual desire, which can help women affected by hypoactive sexual desire disorder (HSDD), decreased sex drive, and difficulty arousing.
The drug is the latest attempt to create a drug that some describe as a "female Viagra," where most have failed so far. Analysts estimate that Vyleesi's turnover may reach $ 1 billion per year.
Behind the company are Palatin Technologies and Amag Pharmaceuticals, whose actions ran for the announcement.
Fixed: In an earlier version, the HSDD task was missing.